Caplin Point Laboratories Limited

NSE CAPLIPOINT.NS

Caplin Point Laboratories Limited EBIT for the year ending March 31, 2024: USD 67.73 M

Caplin Point Laboratories Limited EBIT is USD 67.73 M for the year ending March 31, 2024, a 23.14% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Caplin Point Laboratories Limited EBIT for the year ending March 31, 2023 was USD 55.00 M, a 8.05% change year over year.
Caplin Point Laboratories Limited EBIT for the year ending March 31, 2022 was USD 50.90 M, a 18.25% change year over year.
Caplin Point Laboratories Limited EBIT for the year ending March 31, 2021 was USD 43.05 M, a 19.86% change year over year.
Caplin Point Laboratories Limited EBIT for the year ending March 31, 2020 was USD 35.91 M, a 9.73% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: CAPLIPOINT.NS

Caplin Point Laboratories Limited

CEO	Dr. Sridhar Ganesan
IPO Date	June 23, 2014
Location	India
Headquarters	Ashvich Tower
Employees	3,406
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods Cosmetics

Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

Key trends

Past 5 years